410 related articles for article (PubMed ID: 21239833)
21. A preclinical approach for gene therapy of beta-thalassemia.
Breda L; Kleinert DA; Casu C; Casula L; Cartegni L; Fibach E; Mancini I; Giardina PJ; Gambari R; Rivella S
Ann N Y Acad Sci; 2010 Aug; 1202():134-40. PubMed ID: 20712784
[TBL] [Abstract][Full Text] [Related]
22. Gene Therapy and Genome Editing.
Boulad F; Mansilla-Soto J; Cabriolu A; Rivière I; Sadelain M
Hematol Oncol Clin North Am; 2018 Apr; 32(2):329-342. PubMed ID: 29458735
[TBL] [Abstract][Full Text] [Related]
23. Hemoglobin gene therapy for β-thalassemia.
Bank A
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1187-201. PubMed ID: 21075288
[TBL] [Abstract][Full Text] [Related]
24. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
[TBL] [Abstract][Full Text] [Related]
26. Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies.
Payen E; Leboulch P
Hematology Am Soc Hematol Educ Program; 2012; 2012():276-83. PubMed ID: 23233592
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy for homozygous beta-thalassemia. Is it a reality?
Boulad F; Rivière I; Sadelain M
Hemoglobin; 2009; 33 Suppl 1():S188-96. PubMed ID: 20001625
[TBL] [Abstract][Full Text] [Related]
28. Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted expression from parvovirus B19p6 promoter in primary human hematopoietic progenitor cells.
Kurpad C; Mukherjee P; Wang XS; Ponnazhagan S; Li L; Yoder MC; Srivastava A
J Hematother Stem Cell Res; 1999 Dec; 8(6):585-92. PubMed ID: 10645765
[TBL] [Abstract][Full Text] [Related]
29. The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in beta-thalassemia patients.
Persons DA
Ann N Y Acad Sci; 2010 Aug; 1202():69-74. PubMed ID: 20712775
[TBL] [Abstract][Full Text] [Related]
30. Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy.
Persons DA; Allay ER; Sabatino DE; Kelly P; Bodine DM; Nienhuis AW
Blood; 2001 May; 97(10):3275-82. PubMed ID: 11342459
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
Persons DA; Allay ER; Sawai N; Hargrove PW; Brent TP; Hanawa H; Nienhuis AW; Sorrentino BP
Blood; 2003 Jul; 102(2):506-13. PubMed ID: 12663444
[TBL] [Abstract][Full Text] [Related]
32. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia.
Miccio A; Cesari R; Lotti F; Rossi C; Sanvito F; Ponzoni M; Routledge SJ; Chow CM; Antoniou MN; Ferrari G
Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10547-52. PubMed ID: 18650378
[TBL] [Abstract][Full Text] [Related]
33. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector.
Puthenveetil G; Scholes J; Carbonell D; Qureshi N; Xia P; Zeng L; Li S; Yu Y; Hiti AL; Yee JK; Malik P
Blood; 2004 Dec; 104(12):3445-53. PubMed ID: 15292064
[TBL] [Abstract][Full Text] [Related]
34. Partial correction of murine beta-thalassemia with a gammaretrovirus vector for human gamma-globin.
Nishino T; Tubb J; Emery DW
Blood Cells Mol Dis; 2006; 37(1):1-7. PubMed ID: 16814578
[TBL] [Abstract][Full Text] [Related]
35. Gene therapy for hemoglobinopathies: the state of the field and the future.
Chandrakasan S; Malik P
Hematol Oncol Clin North Am; 2014 Apr; 28(2):199-216. PubMed ID: 24589262
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia.
Sadelain M
Curr Opin Hematol; 2006 May; 13(3):142-8. PubMed ID: 16567956
[TBL] [Abstract][Full Text] [Related]
37. Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia.
Hanawa H; Hargrove PW; Kepes S; Srivastava DK; Nienhuis AW; Persons DA
Blood; 2004 Oct; 104(8):2281-90. PubMed ID: 15198957
[TBL] [Abstract][Full Text] [Related]
38. Gene Therapy Approaches to Hemoglobinopathies.
Ferrari G; Cavazzana M; Mavilio F
Hematol Oncol Clin North Am; 2017 Oct; 31(5):835-852. PubMed ID: 28895851
[TBL] [Abstract][Full Text] [Related]
39. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.
Segura EER; Ayoub PG; Hart KL; Kohn DB
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992422
[TBL] [Abstract][Full Text] [Related]
40. Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients.
Ouyang W; Dong G; Zhao W; Li J; Zhou Z; Yang G; Liu R; Li Y; Zhang Q; Du X; Sun H; Gu Y; Lai Y; Liu S; Liu C
Hum Gene Ther; 2021 May; 32(9-10):481-494. PubMed ID: 33256481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
